Friday 16 October 2026
Export ADCT’s income statement to Excel — free account
ADC Therapeutics SA
ADCT Healthcare Biotechnology
ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.
1.41
0.08
−5.37%
Follow ADCT
ADC Therapeutics SA (ADCT) P/E ratio
ADC Therapeutics SA has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 18 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PYXS Pyxis Oncology, Inc. compare | n/m |
| ADCT ADC Therapeutics SA | n/m |
| LXEO Lexeo Therapeutics, Inc. compare | n/m |
| EVMN Evommune Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| MGNX MacroGenics, Inc. compare | n/m |
| ZNTL Zentalis Pharmaceuticals, Inc. compare | n/m |
| CAMP CAMP4 Therapeutics Corporation compare | n/m |
| LRMR Larimar Therapeutics, Inc. compare | n/m |
| Biotechnology industry median | 8.4× |
| Healthcare sector median | 22.8× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)